EGFR and neoplasm: Transfer of EGFR-Engineered CD8+ lymphocytes in mice bearing B16-OVA (melanoma murine cell lines) and PM299L (hepatocarcinoma cell lines) tumors, led to increased IFN-γ production and delayed tumor growth, respectively, suggesting their potential anti-tumor activity (Fig. 9E) [166].